Schering Corporation

Di-Hwei Hsu

Kevin W Moore

Chuan-Chu Chou

Jimmy C Tan

Ying Liu

Hergen Spits

Alice Suk-Yue Ho

J Fernando Bazan

Albert Zlotnik

Maureen C Howard

Anne O'Garra

Hiroshi Ishida

Rene De Waal Malefyt

Bazan Fernando J

Rene De Malefyt

Receptor components for IL-10 are isolated and characterized. The amino acid sequence and nucleic acid encoding various species variants of the receptors are disclosed. Uses of the purified receptor gene and polypeptide are disclosed, including means for screening for agonists and antagonists of the receptor ligands, for producing diagnostic or therapeutic reagents, and for producing antibodies. Therapeutic or diagnostic reagents and kits are also provided.

Mammalian receptors for interleukin-10

Mammalian receptors for interleukin-10 (IL-10)

Antibodies which specifically bind mammalian receptors for

A method is provided for toting a B cell mediated autoimmune disorder comprising administering an effective amount of an interleukin-10 antagonist.

Use of an interleukin-10 antagonist to treat a B cell mediated

A method is provided for reducing an inflammatory response in a mammal comprising administering to a mammal at risk of developing or afflicted with an inflammatory response characterized by substantially elevated levels of IL-1.alpha., IL-1.beta., IL-6, IL-8 and TNF.alpha., an amount of IL-10 effective to substantially lower the levels of such cytokines.

Use of interleukin-10 analogs for antagonists to treat endotoxin- or

A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.

Use of interleukin-10 (IL-10) to treat endotoxin- or

A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.

Use of interleukin-10 in adoptive immunotherapy of cancer

Growing community of inventors

Palo Alto, CA, United States of America

Di-Hwei Hsu